News | November 07, 2025
AstraZeneca invests additional $136 million to expand Qingdao inhalants facility
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Subscribe To Our Newsletter & Stay Updated
